


Pre- and Post-Survey Results



Ability to identify damage mechanisms included in the traditional understanding of MS pathophysiology


Note: Highlighted p-values are statistically significant



Pre to post: $P < 0.001$




Ability to identify that long-term disability, axonal damage, and response to therapy are positively affected by the early recognition and treatment of MS



Pre to post: $P = 0.037$

N = 242
All Participants


Ability to consider specific patient characteristics and identify actions and goals recommended by the CMSC that can help empower patients with MS



Pre to post: $P = 0.003$




Ability to consider specific patient characteristics and identify the most appropriate first-line treatment for a patient with MS



Pre to post: $P < 0.001$




Ability to identify clinical indicators of suboptimal response to treatment



Pre to post: $P < 0.001$

All Participants

Ability to identify serious safety concerns that are associated with emerging MS therapies




Pre to post: $P = 0.040$

All Participants

Pre-, Post-, and 30-day Survey Results



Ability to identify damage mechanisms included in the traditional understanding of MS pathophysiology




Pre to post: $P = 0.002$

Post to 30-day: $P = 1.000$

Pre to 30-day: $P = 0.002$

Q
Limited Sample

Ability to identify that long-term disability, axonal damage, and response to therapy are positively affected by the early recognition and treatment of MS




Pre to post: $P = 0.698$

Post to 30-day: $P = 0.188$

Pre to 30-day: $P = 0.091$



Ability to consider specific patient characteristics and identify the most appropriate first-line treatment for a patient with MS




Pre to post: $P < 0.001$

Post to 30-day: $P = 0.383$

Pre to 30-day: $P = 0.002$



Ability to identify clinical indicators of suboptimal response to treatment




Pre to post: $P = 0.012$

Post to 30-day: $P = 0.922$

Pre to 30-day: $P = 0.009$



Ability to identify serious safety concerns that are associated with emerging MS therapies



Pre to post: $P = 0.020$

Post to 30-day: $P = 0.166$

Pre to 30-day: $P < 0.001$

